AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 471860 — intervention group
Group type: COMPARATOR
Intervention: Norris Index
Number of subjects: 0
Study 31006930 — intervention group
Group type: COMPARATOR
Intervention: Routine Monitoring
Number of subjects: 464
Study 31006930 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral Prophylactic Mastectomy (CPM)
Number of subjects: 464
Study 31006930 — intervention group
Group type: EXPERIMENTAL
Intervention: Traders (willing to swap between options)
Number of subjects: 464
Study 31006930 — intervention group
Group type: EXPERIMENTAL
Intervention: Less-intrusive monitoring methods
Number of subjects: 464
Study 31006930 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement in decision-making
Number of subjects: 464
Study 31006930 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer concern
Number of subjects: 464
Study 27346393 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-occluded vocal tract exercise with a ventilation mask
Number of subjects: 30
Study 27346393 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ventilation mask)
Number of subjects: 30
Study 25861836 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Number of subjects: 89
Study 25861836 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI-C (FOLFIRI plus cetuximab)
Number of subjects: 89
Study 25861836 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI-C
Number of subjects: 89
Study 23608668 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100 U
Number of subjects: 548
Study 23608668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 548
Study 21666156 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of Edmonston-Zagreb measles vaccine (MV) at 6 and 9 months
Number of subjects: 22
Study 21666156 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of Edmonston-Zagreb measles vaccine (MV) at 6 and 9 months
Number of subjects: 22
Study 21666156 — intervention group
Group type: COMPARATOR
Intervention: Control group: Measles vaccine at 9 months only (for HIV-uninfected children)
Number of subjects: 22
Study 21666156 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected children receiving measles vaccine
Number of subjects: 22
Study 19626051 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab monotherapy as first-line therapy
Number of subjects: 0
Study 19626051 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab treatment
Number of subjects: 0
Study 19626051 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring CMV reactivation
Number of subjects: 0
Study 19626051 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of alemtuzumab
Number of subjects: 0
Study 19626051 — intervention group
Group type: COMPARATOR
Intervention: Alemtuzumab combination therapy and consolidation therapy
Number of subjects: 0
Study 16939937 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair analysis using immunoassay techniques
Number of subjects: 382
Study 16939937 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported frequency of heroin use
Number of subjects: 382
Study 16939937 — intervention group
Group type: EXPERIMENTAL
Intervention: Sectional hair analysis
Number of subjects: 382
Study 14695461 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium (n=89)
Number of subjects: 180
Study 14695461 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group, n=91)
Number of subjects: 180
Study 11236832 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.56 g/kg alcohol with reinforcement (money and verbal approval)
Number of subjects: 32
Study 11236832 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.56 g/kg alcohol without reinforcement
Number of subjects: 32
Study 11236832 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo with reinforcement (money and verbal approval)
Number of subjects: 32
Study 11236832 — intervention group
Group type: COMPARATOR
Intervention: Placebo without reinforcement
Number of subjects: 32
Study 11236832 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.56 g/kg alcohol
Number of subjects: 32
Study 11236832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 9310521 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamphetamine (DEX) 0.15 mg/kg/dose
Number of subjects: 125
Study 9310521 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.3 mg/kg/dose
Number of subjects: 125
Study 9310521 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 125
Study 9310521 — intervention group
Group type: COMPARATOR
Intervention: Dexamphetamine (DEX) vs Methylphenidate (MPH)
Number of subjects: 125
Study 8418717 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg intravenously
Number of subjects: 300
Study 8418717 — intervention group
Group type: COMPARATOR
Intervention: Citrate alone
Number of subjects: 300
Study 8418717 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine/citrate
Number of subjects: 300
Study 8418717 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (given more than 30 min before PI sample)
Number of subjects: 300
Study 3805657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg nightly)
Number of subjects: 59
Study 3805657 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate (2 g/day)
Number of subjects: 59
Study 30961937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1082
Study 28727639 — intervention group
Group type: EXPERIMENTAL
Intervention: MCI-EX (12-week resistance exercise program with elastic band)
Number of subjects: 22
Study 28727639 — intervention group
Group type: EXPERIMENTAL
Intervention: NG-EX (12-week resistance exercise program with elastic band)
Number of subjects: 22
Study 28727639 — intervention group
Group type: COMPARATOR
Intervention: MCI-Con (control group)
Number of subjects: 22
Study 28727639 — intervention group
Group type: COMPARATOR
Intervention: NG-Con (control group)
Number of subjects: 22
Study 27447948 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative primary care for PTSD and depression
Number of subjects: 474
Study 27447948 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate combat exposure
Number of subjects: 474
Study 27447948 — intervention group
Group type: EXPERIMENTAL
Intervention: High combat exposure
Number of subjects: 474
Study 24749987 — intervention group
Group type: EXPERIMENTAL
Intervention: Theatre and surgical wards
Number of subjects: 16
Study 24749987 — intervention group
Group type: EXPERIMENTAL
Intervention: Theatre and departmental office
Number of subjects: 16
Study 24749987 — intervention group
Group type: COMPARATOR
Intervention: Restricted to theatre only
Number of subjects: 16
Study 23130649 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg GMZ2 vaccine in pre-school children
Number of subjects: 2
Study 23130649 — intervention group
Group type: EXPERIMENTAL
Intervention: GMZ2 vaccine in vaccinated adults
Number of subjects: 2
Study 20538749 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus OMM
Number of subjects: 34
Study 20538749 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 34
Study 17021884 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron 1 mg/kg body weight during surgery
Number of subjects: 40
Study 17021884 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 ml saline)
Number of subjects: 40
Study 16206603 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (n=28)
Number of subjects: 80
Study 16206603 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (n=26)
Number of subjects: 80
Study 16206603 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril + Valsartan (n=26)
Number of subjects: 80
Study 12431323 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (cisplatin-based regimens)
Number of subjects: 4
Study 12431323 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 4
Study 10901600 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite posterior material with barium-aluminium silicate (radiopaque)
Number of subjects: 137
Study 10901600 — intervention group
Group type: COMPARATOR
Intervention: Composite posterior material without barium-aluminium silicate (not radiopaque)
Number of subjects: 137
Study 7737712 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (10 to 20 mg)
Number of subjects: 79
Study 7737712 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 to 100 mg)
Number of subjects: 79
Study 7737712 — intervention group
Group type: COMPARATOR
Intervention: Normotensive control subjects
Number of subjects: 79
Study 2390186 — intervention group
Group type: COMPARATOR
Intervention: Oral solution (OS) containing the concentrated official formula in packets (group A)
Number of subjects: 100
Study 2390186 — intervention group
Group type: COMPARATOR
Intervention: Commercially prepared ready‐to‐use OS (group B)
Number of subjects: 100
Study 7011359 — intervention group
Group type: EXPERIMENTAL
Intervention: RePUVA (retinoid plus PUVA)
Number of subjects: 80
Study 7011359 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinoid alone (Tigason)
Number of subjects: 80
Study 7011359 — intervention group
Group type: COMPARATOR
Intervention: PUVA alone
Number of subjects: 80
Study 31109126 — intervention group
Group type: EXPERIMENTAL
Intervention: Cascade Ensemble Learning (CELearning) model using XGBoost, Random Forest, ExtraTrees, and Softmax Regression; details on dosage and duration not applicable as this is a computational model.
Number of subjects: 0
Study 27807887 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol 480 mg/day for 4 weeks
Number of subjects: 43
Study 27807887 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules for 4 weeks
Number of subjects: 43
Study 26019248 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein dissolved in bovine milk serum (Cas+Serum)
Number of subjects: 32
Study 26019248 — intervention group
Group type: COMPARATOR
Intervention: Micellar casein only (Cas)
Number of subjects: 32
Study 24121143 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri (LR) 10^10 colony-forming units, 5 drops per day for 6 months
Number of subjects: 61
Study 24121143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 24121143 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri (LR)
Number of subjects: 61
Study 21098476 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-dose group (500 mg oral dose 2 hours before procedure)
Number of subjects: 414
Study 21098476 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose group (500 mg oral dose 2 hours before procedure and an additional dose 8 hours later)
Number of subjects: 414
Study 21098476 — intervention group
Group type: COMPARATOR
Intervention: Both groups (1-dose and 2-dose)
Number of subjects: 414
Study 19943593 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic approach
Number of subjects: 83
Study 19943593 — intervention group
Group type: COMPARATOR
Intervention: Open approach
Number of subjects: 83
Study 19199220 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle tape
Number of subjects: 20
Study 19199220 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-rigid ankle brace
Number of subjects: 20
Study 19199220 — intervention group
Group type: COMPARATOR
Intervention: Control (no stabilizer)
Number of subjects: 20
Study 15657411 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention grounded in social cognitive theory, consisting of five group sessions focused on enhancing motivation and developing coping efficacy skills.
Number of subjects: 0
Study 15657411 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 0
Study 11935164 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral injections of corticosteroids
Number of subjects: 28
Study 10803113 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfilled resin (Silux Plus, 3M, USA)
Number of subjects: 28
Study 10803113 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid minifilled composite resin (Herculite XRV, Kerr, USA)
Number of subjects: 28
Study 7575694 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenidap 120 mg/day
Number of subjects: 0
Study 7575694 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine 400 mg/day plus Piroxicam 20 mg/day
Number of subjects: 0
Study 7575694 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg/day
Number of subjects: 0
Study 2403063 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms vitamin D daily for 6 weeks
Number of subjects: 30
Study 2403063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7013586 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole as an adjunct to routine chemotherapy
Number of subjects: 50
Study 7013586 — intervention group
Group type: COMPARATOR
Intervention: Routine chemotherapy for tuberculosis only (Control)
Number of subjects: 50
Study 31340880 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal BMI at follow-up
Number of subjects: 889
Study 31340880 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 889
Study 31340880 — intervention group
Group type: EXPERIMENTAL
Intervention: Snacking dietary pattern
Number of subjects: 889
Study 31340880 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked foods dietary pattern
Number of subjects: 889
Study 31340880 — intervention group
Group type: COMPARATOR
Intervention: Gender comparison (Boys vs Girls)
Number of subjects: 889
Study 29340678 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass + lifestyle-intensive medical management
Number of subjects: 120
Study 29340678 — intervention group
Group type: COMPARATOR
Intervention: lifestyle-intensive medical management
Number of subjects: 120
Study 26362593 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal mandibulectomy
Number of subjects: 38
Study 26362593 — intervention group
Group type: EXPERIMENTAL
Intervention: Glossectomy
Number of subjects: 38
Study 26362593 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental mandibulectomy
Number of subjects: 38
Study 26362593 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 38
Study 24136368 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glycerol
Number of subjects: 360
Study 24136368 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal acetaminophen
Number of subjects: 360
Study 24136368 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies (glycerol and acetaminophen)
Number of subjects: 360
Study 24136368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 23304075 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 10 mL of 0.5% bupivacaine
Number of subjects: 0
Study 23304075 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: 10 mL of 0.5% bupivacaine on one side and 10 mL of normal saline (NSS) placebo on the opposite side
Number of subjects: 0
Study 23304075 — intervention group
Group type: COMPARATOR
Intervention: Group C: 10 mL of NSS placebo per side
Number of subjects: 0
Study 23304075 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 20438534 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct adsorption of lipoproteins (DALI)
Number of subjects: 19
Study 20438534 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin‐induced LDL‐precipitation (HELP)
Number of subjects: 19
Study 20438534 — intervention group
Group type: EXPERIMENTAL
Intervention: Double filtration plasmapheresis (DFPP)
Number of subjects: 19
Study 20438534 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL apheresis (all methods combined)
Number of subjects: 19
Study 18356633 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional amikacin dosing
Number of subjects: 40
Study 16544143 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel 75 mg/m2 and cisplatin 75 mg/m2
Number of subjects: 15
Study 16544143 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel 75 mg/m2, cisplatin 75 mg/m2, and 5‐FU 750 mg/m2/day
Number of subjects: 15
Study 12913205 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 110
Study 12913205 — intervention group
Group type: COMPARATOR
Intervention: Electrophysiology
Number of subjects: 110
Study 11286111 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK procedure
Number of subjects: 112
Study 8911706 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine eye drops (0.5 mg/mL)
Number of subjects: 10
Study 8911706 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine at 2 x 10(‐5) M concentration
Number of subjects: 10
Study 1918421 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 25 mg three times a day
Number of subjects: 60
Study 1918421 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 75 mg three times a day
Number of subjects: 60
Study 1918421 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 125 mg three times a day
Number of subjects: 60
Study 1918421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7143458 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy focused on obtaining orgasm through self‐stimulation
Number of subjects: 4
Study 31986526 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse home visits (NHVs)
Number of subjects: 0
Study 31986526 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease management clinics
Number of subjects: 0
Study 31986526 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse case management
Number of subjects: 0
Study 31986526 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 31118458 — intervention group
Group type: EXPERIMENTAL
Intervention: SnCl2/AmF/NaF-containing mouth rinse and toothpaste
Number of subjects: 54
Study 31118458 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study 28759734 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy beverage
Number of subjects: 26
Study 28759734 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 26
Study 28759734 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk and yogurt beverage
Number of subjects: 26
Study 28759734 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 26
Study 28759734 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy and nondairy beverages
Number of subjects: 26
Study 28759734 — intervention group
Group type: EXPERIMENTAL
Intervention: All beverages
Number of subjects: 26
Study 28759734 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy beverages
Number of subjects: 26
Study 28759734 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 26
Study 26192044 — intervention group
Group type: EXPERIMENTAL
Intervention: Quotations condition (90-min relevance intervention)
Number of subjects: 1916
Study 26192044 — intervention group
Group type: EXPERIMENTAL
Intervention: Text condition (90-min relevance intervention)
Number of subjects: 1916
Study 26192044 — intervention group
Group type: COMPARATOR
Intervention: Control condition (waiting control)
Number of subjects: 1916
Study 23591256 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study 23591256 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 21326120 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure therapy for 4 weeks
Number of subjects: 45
Study 19251872 — intervention group
Group type: EXPERIMENTAL
Intervention: Laughter (30-minute film segment)
Number of subjects: 18
Study 19251872 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Stress (30-minute film segment)
Number of subjects: 18
Study 18061058 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol (1 mmol/L lower)
Number of subjects: 900000
Study 18061058 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol
Number of subjects: 900000
Study 18061058 — intervention group
Group type: EXPERIMENTAL
Intervention: Total/HDL cholesterol ratio
Number of subjects: 900000
Study 15134763 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-related functional magnetic resonance imaging (fMRI) during attentional blink paradigm
Number of subjects: 0
Study 11561919 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach emotional state
Number of subjects: 152
Study 11561919 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal emotional state
Number of subjects: 152
Study 11561919 — intervention group
Group type: COMPARATOR
Intervention: Neutral emotional state
Number of subjects: 152
Study 9585795 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (300 mg on day 15, 400 mg on day 16, and 500 mg on days 17 to 24)
Number of subjects: 16
Study 9585795 — intervention group
Group type: COMPARATOR
Intervention: Rifabutin (150 mg daily for 24 days) with placebo
Number of subjects: 16
Study 8148935 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish version of an educational program designed to be an adjuvant to adequate medical care
Number of subjects: 138
Study 8148935 — intervention group
Group type: COMPARATOR
Intervention: Adequate care from the research staff (after trial termination)
Number of subjects: 138
Study 3127076 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous NTG combined with intravenous NAC (5 g 6 hourly)
Number of subjects: 46
Study 3127076 — intervention group
Group type: COMPARATOR
Intervention: Intravenous NTG alone
Number of subjects: 46
Study 3127076 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous NTG and continuously infused NAC (10 g/day)
Number of subjects: 46
Study 30138668 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200/300 mg every 2 weeks
Number of subjects: 465
Study 30138668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 465
Study 27347863 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg strengthening group (IG); n = 19
Number of subjects: 40
Study 27347863 — intervention group
Group type: COMPARATOR
Intervention: Active control group (CG); n = 17
Number of subjects: 40
Study 26121725 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sucrose prior to echocardiography
Number of subjects: 104
Study 26121725 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oral sucrose)
Number of subjects: 104